Literature DB >> 19900774

Inner ear pathology of alpha-galactosidase A deficient mice, a model of Fabry disease.

Yuika Sakurai1, Rie Suzuki, Ryuichi Yoshida, Hiromi Kojima, Michiko Watanabe, Yoshinobu Manome, Toya Ohashi, Yoshikatu Eto, Hiroshi Moriyama.   

Abstract

OBJECTIVE: Fabry disease is characterized by genetic alpha-galactosidase A deficiency, resulting in accumulation of glycolipids (GL-3) and tissue damage. Hearing loss is also common and attributed to GL-3 accumulation in the inner ear. The only reported histological studies dealt with murine and human specimens. Accordingly, histopathological studies of the cochlea were performed on an alpha-galactosidase A deficient murine model of Fabry disease, using C57BL6/J mice as the controls.
METHODS: The hearing ability was evaluated using the ABR threshold, while cochlear specimens were observed light microscopically and ultrathin temporal bone sections by TEM.
RESULTS: HE staining showed no accumulation of GL-3 or abnormal cochlear morphology in the alpha-galactosidase A deficient mice, but toluidine blue staining and TEM revealed GL-3 accumulation in the stria vascularis and kidney. No GL-3 accumulation was detected in the C57BL6/J controls by either HE staining or TEM. The alpha-galactosidase A deficient mice and the controls showed no clear differences in the ABR threshold (hearing acuity), but for older animals the threshold was higher in the C57BL6/J controls.
CONCLUSION: In summary, although the alpha-galactosidase A deficient mice showed no clear hearing loss, GL-3 accumulation was demonstrated in the cochlea. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19900774     DOI: 10.1016/j.anl.2009.08.005

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  6 in total

1.  Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy.

Authors:  Eefje B Suntjens; Bouwien E Smid; Marieke Biegstraaten; Wouter A Dreschler; Carla E M Hollak; Gabor E Linthorst
Journal:  J Inherit Metab Dis       Date:  2014-11-14       Impact factor: 4.982

Review 2.  Hearing loss and renal syndromes.

Authors:  Paul J Phelan; Michelle N Rheault
Journal:  Pediatr Nephrol       Date:  2017-11-12       Impact factor: 3.714

Review 3.  Progress in the understanding and treatment of Fabry disease.

Authors:  James J Miller; Adam J Kanack; Nancy M Dahms
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-09-14       Impact factor: 3.770

4.  Otological aspects of Fabry disease in patients with normal hearing.

Authors:  Fei Wang; Hiroshi Yamamoto; Tadao Yoshida; Satofumi Sugimoto; Masaaki Teranishi; Kazuya Tsuboi; Michihiko Sone
Journal:  Nagoya J Med Sci       Date:  2019-08       Impact factor: 1.131

5.  Balance control impairments in Fabry disease.

Authors:  Laetitia Peultier-Celli; Roland Jaussaud; Pierre Kaminsky; Joëlle Deibener-Kaminsky; François Feillet; Philippe Perrin
Journal:  Front Neurol       Date:  2022-09-30       Impact factor: 4.086

6.  Long-term effect of enzyme replacement therapy with fabry disease.

Authors:  Manabu Komori; Yuika Sakurai; Hiromi Kojima; Toya Ohashi; Hiroshi Moriyama
Journal:  Int J Otolaryngol       Date:  2013-10-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.